MEDI4893

DRUG2 trials

Sponsors

MedImmune LLC

Conditions

Staphylococcus AureusStaphylococcus Aureus Pneumonia

Phase 1

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

CompletedNCT01769417

MedImmune LLCStaphylococcus Aureus

Start: 2013-01-31End: 2014-05-31Updated: 2014-07-24

Phase 2

Study of the Efficacy and Safety of MEDI4893

CompletedNCT02296320

MedImmune LLCStaphylococcus Aureus Pneumonia

Start: 2014-10-10End: 2018-10-02Updated: 2019-12-23

Related Papers

Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.

2021-04-2168 citations

1486. Phylogenetic and alpha toxin variant analyses of <i>Staphylococcus aureus</i> strains isolated from patients during the SAATELLITE study

Open Forum Infectious Diseases2020-10-01

2839. Efficacy, Pharmacokinetics (PK), and Safety Profile of Suvratoxumab (MEDI4893), a Staphylococcus aureus Alpha Toxin (AT)-Neutralizing Human Monoclonal Antibody in Mechanically Ventilated Patients in Intensive Care Units; Results of the Phase 2 SAATELLITE Study Conducted by the Public-Private COMBACTE Consortium

Open Forum Infectious Diseases2019-10-015 citations

2160. Performance of the Cepheid Rapid PCR Test for Patient Screening and Association with Efficacy of Suvratoxumab, A Novel Anti-Staphylococcus aureus Monoclonal Antibody, During the Phase 2 SAATELLITE study

Open Forum Infectious Diseases2019-10-012 citations

1557. Population Pharmacokinetics of Suvratoxumab (MEDI4893), an Extended Half-life Staphylococcus aureus Alpha Toxin-Neutralizing Human Monoclonal Antibody, in Healthy Adults and Patients on Mechanical Ventilation in Intensive Care Units

Open Forum Infectious Diseases2019-10-01

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

Antimicrobial Agents and Chemotherapy2016-10-18134 citations